NCT05186064Completed
Glioblastoma Targeted Treatment Option Maximization by WGS
Glioblastoma Targeted Treatment Option Maximization by Whole Genome Sequencing
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates. 160 patients that will undergo re-resection in the GLOW study will be presented with WGS results leading to added treatment options.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 164 (actual)
- First submitted
- 23 Dec 2021
- Start date
- 25 Jul 2022
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- UMC Utrecht
- Diseases
- Glioblastoma
- NCT number
- NCT05186064
What you commit to
- Study type: Interventional
- Participants enrolled: 164
- From 25 Jul 2022 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in medication studies or which could jeopardize compliance with study requirements including, but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
Other
- Currently actively treated in another antitumor clinical trial (excluding DRUP and STELLAR studies);
Who the study is looking for
- Histopathologically confirmed IDH wild type glioblastoma, first recurrence after standard chemoradiation; suitable for standard-of-care re-resection;
- Age ≥ 18 years;
- Able and willing to give written informed consent;
- Life expectancy \>3 months, allowing adequate follow-up of toxicity evaluation and antitumor activity;
- KPS performance status ≥70.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haaglanden Medisch Centrum Coordinator of this site? Confirm its status | The Hague | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.